[ad_1]
DoorDash Inc.’s third-quarter forecast for a key demand metric on Thursday came in above Wall Street’s expectations, but the delivery app lost more than expected during the second quarter, as it invests in expanding what — and where — it delivers.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...